Skip to main content
Veterinary Medicines

Masti Veyxym intramamálna mast'

Authorised
  • Chymotrypsin
  • Trypsin
  • Papain
  • Retinol palmitate
  • ALPHATOCOPHEROL ACETATE

Product identification

Medicine name:
Masti Veyxym intramamálna mast'
Active substance:
  • Chymotrypsin
  • Trypsin
  • Papain
  • Retinol palmitate
  • ALPHATOCOPHEROL ACETATE
Target species:
  • Cattle (cow)
Route of administration:
  • Intramammary use

Product details

Active substance and strength:
  • Chymotrypsin
    2400.00
    FIP
    /
    1.00
    Syringe
  • Trypsin
    240.00
    FIP
    /
    1.00
    Syringe
  • Papain
    6.00
    FIP
    /
    1.00
    Syringe
  • Retinol palmitate
    100000.00
    international unit(s)
    /
    1.00
    Syringe
  • ALPHATOCOPHEROL ACETATE
    120.00
    milligram(s)
    /
    1.00
    Syringe
Pharmaceutical form:
  • Intramammary ointment
Withdrawal period by route of administration:
  • Intramammary use
    • Cattle (cow)
      • Meat and offal
        0
        day
      • Milk
        1
        day
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QG52X
Authorisation status:
  • Valid
Authorised in:
  • Slovakia
Available in:
  • Slovakia
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Marketing authorisation holder:
  • Veyx Pharma GmbH
Marketing authorisation date:
Manufacturing sites for batch release:
  • Veyx Pharma GmbH
Responsible authority:
  • Institute For State Control Of Veterinary Biologicals And Medicaments
Authorisation number:
  • 96/161/94-S
Date of authorisation status change:

Documents

Combined File of all Documents

This document does not exist in this language (English). You can find it in another language below.
Slovak (PDF)
Published on: 30/06/2023
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."